Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Botanical or Opioid or [[:Category:Antiparkinsonians|Antiparkinsonian]]

Use the filters below to narrow your results.

generic:
Codeine (2)
brand:
None (32) · (multiple, generic dominant) (1) · Alfenta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Heroin (1) · Krokodil (1) · Mirapex (IR), Mirapex ER (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Requip (IR), Requip XL (extended-release) (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · None (2) · Contains LSA (2) · Contains mescaline (2)
uses:
None (51) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1)
starting dose:
None (51) · Adult: 15–60 mg every 4 hours as needed. (1) · Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed (1) · Parkinson disease: 0.25 mg PO TID, titrate weekly. Restless legs syndrome: 0.25 mg PO 1-3 hours before bedtime, titrate to 4 mg/day if needed (1)
preparations:
None (51) · IR tablets 0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tablets 0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg (1) · IR tablets 0.25, 0.5, 1, 2, 3, 4, 5 mg; XL tablets 2, 4, 6, 8, 12 mg (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (51) · 24 mg/day (Parkinson disease); 4 mg/day (restless legs syndrome) (1) · 360 mg/day (1) · 4.5 mg/day (Parkinson disease); 0.5 mg/day (restless legs syndrome) (1)
routes:
None (51) · Oral (2) · PO (only formulation marketed in the US). (1)
onset:
None (51) · 30–60 min (PO) (1) · Motor improvement over days at therapeutic dose (2)
duration:
None (51) · 4–6 hours (1) · TID dosing (IR); once-daily (ER) (1) · TID dosing (IR); once-daily (XL) (1)
halflife:
None (51) · 2.5–3 hours (1) · 8-12 hours (longer in elderly and renal impairment)'"`UNIQ--ref-0000001B-QINU`"' (1) · ~6 hours'"`UNIQ--ref-00000015-QINU`"' (1)
bioavailability:
None (51) · >90% (oral)'"`UNIQ--ref-0000001C-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~55% (oral)'"`UNIQ--ref-00000016-QINU`"' (1)
pregnancy:
None (51) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited human data; rarely indicated in pregnancy given the typical patient population.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (51) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 57 results in range #1 to #57.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"